PAN-90806
CAS No. 252003-65-9
PAN-90806( CP-547632 | CP547632 )
Catalog No. M13744 CAS No. 252003-65-9
PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 76 | Get Quote |
|
| 10MG | 120 | Get Quote |
|
| 25MG | 246 | Get Quote |
|
| 50MG | 475 | Get Quote |
|
| 100MG | 691 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePAN-90806
-
NoteResearch use only, not for human use.
-
Brief DescriptionPAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
-
DescriptionPAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM); is approximately equipotent (<10-fold) against VEGFR-2, bFGF receptor and EGFR/Tie-2 chimera, 250-1000-fold selectivity over PDGFRβ, EGFR and InsR; inhibits tumor-associated VEGFR-2 phosphorylation with decreased microvascular density and significant tumor growth inhibition in a number of tumor models.
-
In VitroCP-547632 (1-1000 nM; 1 hours) inhibits VEGF-stimulated VEGFR-2 phosphorylation in a dose-dependent fashion, with an IC50 value of 6 nM. Western Blot Analysis Cell Line:Serum-deprived cells Concentration:1, 4, 16, 63, 250, 1000 nM Incubation Time:1 hours Result:Inhibited VEGF-stimulated VEGFR-2 phosphorylation in a dose-dependent fashion.
-
In VivoCP-547632 (p.o.; 6.25-100 mg/kg/day; for 10-24 days) causes a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts. CP-547632 (oral; 50 mg/kg; a single oral dose) yieldes plasma concentrations above 500 ng/ml for 12 hours. Animal Model:Athymic female mice (CD-1 nu/nu) bearing tumors (75-150 mm in size)Dosage:6.25, 12.5, 25, 50, 100 mg/kg Administration:PO; daily; 10-24 days Result:Caused a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts.Animal Model:Female athymic mice bearing H-Ras tumor Dosage:50 mg/kg Administration:Oral Result:A single oral dose of 50 mg/kg yielded plasma concentrations above 500 ng/ml for 12 hours.
-
SynonymsCP-547632 | CP547632
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number252003-65-9
-
Formula Weight532.4
-
Molecular FormulaC20H24BrF2N5O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (187.83 mM)
-
SMILESO=C(C1=C(NC(NCCCCN2CCCC2)=O)SN=C1OCC3=C(F)C=C(Br)C=C3F)N
-
Chemical Name3-((4-bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Beebe JS, et al. Cancer Res. 2003 Nov 1;63(21):7301-9.
2. Cohen RB, et al. Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9.
molnova catalog
related products
-
N-Desethyl Sunitinib
N-Desethyl Sunitinib is a sunitinib metabolite.
-
PKI-166
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
-
Apatinib Mesylate
Apatinib (YN968D1) is a multitargeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR-2 (Flk-1/KDR, IC50=1 nM), RET, c-Kit and c-Src (IC50=13, 429 and 530 nM respectively).
Cart
sales@molnova.com